会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Method of treating cerebral ischemia with hydrogenation products of frankincense extracts
    • 用乳香提取物氢化产物治疗脑缺血的方法
    • US07645461B2
    • 2010-01-12
    • US10549323
    • 2004-03-18
    • Frank StriggowWerner SchmidtTill Mack
    • Frank StriggowWerner SchmidtTill Mack
    • A61K36/00A61K31/00A01K26/00A01N61/00
    • A61K31/19A61K36/324
    • The invention relates to the use of the hydrogenation products of frankincense (olibanum), its hydrogenated ingredients as well as physiologically acceptable salts and derivatives thereof and hydrogenated frankincense extracts for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia, cranial/brain trauma and/or Alzheimer's disease. The use of frankincense, frankincense extract, substances contained in frankincense, their physiologically acceptable salts, their derivatives and the physiological salts thereof, pure boswellic acids, tirucallic acids or other triterpenes, their physiologically acceptable salts, derivatives of the salts thereof for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia and/or cranial/brain trauma is also provided according to the invention.
    • 本发明涉及乳香(olibanum)的氢化产物,其氢化成分及其生理上可接受的盐和衍生物以及氢化乳香提取物在制备用于预防和/或治疗性脑缺血的药物中的用途, 颅脑/脑创伤和/或阿尔茨海默氏病。 使用乳香,乳香提取物,乳香中含有的物质,其生理学上可接受的盐,其衍生物及其生理盐,纯的保乳酸,铁金属酸或其他三萜烯,其生理学上可接受的盐,其盐的衍生物,用于生产 根据本发明还提供了用于预防和/或治疗脑缺血和/或颅/脑创伤的药物。
    • 2. 发明申请
    • Use of incense or hydrogenation products for preventing and/or treating a cerebral ischemia and/or cerebral traumatic lesion
    • 使用香或氢化产品预防和/或治疗脑缺血和/或脑创伤病变
    • US20060177467A1
    • 2006-08-10
    • US10549323
    • 2004-03-18
    • Frank StriggowWerner SchmidtTill Mack
    • Frank StriggowWerner SchmidtTill Mack
    • A61K36/324A61K31/19
    • A61K31/19A61K36/324
    • The invention relates to the use of the hydrogenation products of frankincense (olibanum), its hydrogenated ingredients as well as physiologically acceptable salts and derivatives thereof and hydrogenated frankincense extracts for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia, cranial/brain trauma and/or Alzheimer's disease. The use of frankincense, frankincense extract, substances contained in frankincense, their physiologically acceptable salts, their derivatives and the physiological salts thereof, pure boswellic acids, tirucallic acids or other triterpenes, their physiologically acceptable salts, derivatives of the salts thereof for the production of a medicament for the prophylactic and/or therapeutic treatment of cerebral ischemia and/or cranial/brain trauma is also provided according to the invention.
    • 本发明涉及乳香(olibanum)的氢化产物,其氢化成分及其生理上可接受的盐和衍生物以及氢化乳香提取物在制备用于预防和/或治疗性脑缺血的药物中的用途, 颅脑/脑创伤和/或阿尔茨海默氏病。 使用乳香,乳香提取物,乳香中含有的物质,其生理学上可接受的盐,其衍生物及其生理盐,纯的保乳酸,铁金属酸或其他三萜烯,其生理学上可接受的盐,其盐的衍生物,用于生产 根据本发明还提供了用于预防和/或治疗脑缺血和/或颅/脑创伤的药物。
    • 8. 发明申请
    • DEVICE FOR STIMULATION BY MEANS OF ELECTRIC AND MAGNETIC FIELDS, AND FIELD APPLICATORS FOR THIS PURPOSE
    • US20090248098A1
    • 2009-10-01
    • US12303389
    • 2006-08-31
    • Stewart PennyManfred KraussRoland FischerWerner SchmidtMario Möbius
    • Stewart PennyManfred KraussRoland FischerWerner SchmidtMario Möbius
    • A61N2/04A61N1/36
    • A61N2/006A61N1/32A61N2/02
    • A device for stimulation via special electric and magnetic fields and optimized field applicators is provided. Derived from human physiology, the autonomic/vegetative nervous system, specifically its sympathetic and parasympathetic components, can be controlled by signals in the frequency ranges of 0.05 to 0.15 Hz and of 0.15 to 0.30 Hz, respectively. Along with other components, these constitute integral parts of corresponding modular physical cardiovascular stimulation programs. By addition of characteristic sinusoidal oscillations, including a positive or negative electric field between the head area and a peripheral area of a human or animal, with the corresponding low-frequency sympathetic or parasympathetic control frequency as base oscillation and with application-typical EEG frequencies and higher-frequency sinusoidal oscillations in the range of ca. 250 to 1500 Hz, characteristic stimulation programs can be established in modular configuration. The introduction of the information parameters for the sympathetic and parasympathetic components, via physical stimulation in the area of the spinal cord, the principal part of the central nervous system, is effected by the field applicators being embodied such that, in the upper body area, a concentration of the magnetic flux, which is generated by a mat applicator, is established in the center of the body, and, likewise on the basis of the physiological relationships in the lower half of the body, the associated mat applicator system is embodied such that the field energy is distributed to both leg areas, and two field strength maxima are thus obtained. To allow the advantage of stimulation via the electric potentials to be combined with the input of the magnetic field effects, a field applicator is equipped with a combination of a magnetic-field-generating coil arrangement and of an electrode arrangement generating the electric field. The electrode generating the electric field can at the same time be designed as a magnetic-field-generating coil.